|Articles|July 10, 2020
NeurologyLive Friday 5 — July 10, 2020
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.
Advertisement
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Biogen Files Aducanumab BLA for Alzheimer Disease
Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.
2: Insights: Practical Advice on the Management of PD OFF Episodes
Concluding his discussion on Parkinson disease OFF episodes management, Peter LeWitt, MD, shares practical advice regarding the use of on-demand therapy.
3: COVID-19 Linked to Potential New Neurologic Symptoms in Children
One of the first case-series studies that analyzed children with COVID-19 suggests that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.
4: Neurology Groups Come Together to Support Continued Telemedicine Service, Payment Parity
Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.
5: News Network: Brivaracetam in Children With PGS or Mixed Seizure Types
Anup Patel, MD, offers considerations for recent data with adjunctive brivaracetam in pediatric patients with primary generalized seizures or mixed seizure types.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
5